ClinicalTrials.gg
TerminatedNCT03344003PREVAILUpdated Aug 9, 2024Results posted

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq

An observational study in Hemophilia A, sponsored by Octapharma. Terminated at 3 sites in Canada. Open to male participants. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Octapharma · Observational

Why this study was terminated
Study terminated as enrolled patients rolled over into a large international study in the same indication

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
14
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Hemophilia A by Octapharma — 3 open to participants now, 3 under way, none of them phase 3. Hemophilia A · Octapharma.

Started
2018
with 1 other
Observational
3 of 15
1 open now
Registered
10th of 15
by date

Among the 15 studies in Hemophilia A by Octapharma, this one is one of 2 that started in 2018, is one of 3 observational ones, and was the 10th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

3 of the 15 studies in Hemophilia A by Octapharma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hemophilia A by Octapharma, or all of them as a file.
02

Study summary

Uncontrolled, multi-centre, non-interventional study with a prospective and a retrospective cohort, to evaluate the efficacy of Wilate or Nuwiq in achieving complete or partial immune tolerance induction (ITI) success in severe and moderate haemophilia A patients with inhibitors

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A total of at least 80 patients were planned, at least 40 in the prospective cohort and 40 in the retrospective cohort. Due to study termination, only 14 patients were enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients of any age with moderate or severe haemophilia A.
  • Patients with a first occurrence of inhibitors, inhibitors to previous ITI attempt(s), or relapsed inhibitors to FVIII, with an inhibitor titre of ≥0.6 BU measured on 2 separate occasions at least 2 weeks apart.
  • Informed written consent from the patient and/or the patient's parent(s) or legal guardian(s)

For patients in the prospective cohort:

  • Patients who are currently on Wilate or Nuwiq ITI, have just initiated ITI, or are planned to initiate ITI treatment with Wilate or Nuwiq.

For patients in the retrospective cohort:

  • Patients having received Wilate or Nuwiq ITI before entry into this study. Retrospective data will be collected for a maximum of 3 years before enrolment into the study. To be eligible, the following information is needed:
  • Wilate or Nuwiq treatment details (start date, dose, treatment frequency, and dose change).
  • Reliably documented bleeding frequency.
  • FVIII inhibitor titres.
  • FVIII half-life.
  • FVIII IVR.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria are not eligible for the study:

  • Congenital or acquired bleeding disorders other than haemophilia A.
  • A history of to blood products and/or plasma-derived FVIII concentrates.
  • Inability to speak/read English or French well enough to provide consent and adhere to the study.
  • People who are receiving other non-factor therapies, e.g. concizumab
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
14 participants (actual)
Patient registry
No

Groups and cohorts

  • Wilate or Nuwiq prospective cohort

    Evaluable haemophilia A patients with an inhibitor against FVIII enrolled prospectively

    Drug: Wilate or Nuwiq

  • Wilate or Nuwiq retrospective cohort

    Evaluable haemophilia A patients with an inhibitor against FVIII enrolled retrospectively

    Drug: Wilate or Nuwiq

Interventions

  • DrugWilate or Nuwiq

    Wilate or Nuwiq administered via intravenous injection

    Also known as: Wilate: Human von Willebrand factor / human coagulation factor VIII. Nuwiq: recombinant factor VIII (rhFVIII)

06

What researchers measure

Primary outcomes

  1. Number of Moderate and Severe Haemophilia A Patients With Inhibitors Achieving Complete or Partial Immune Tolerance Induction (ITI) Success

    ITI success will be determined using predefined success criteria to analyze the proportion of patients achieving complete or partial ITI success. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre \<0.6BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental in vivo recovery (IVR) of FVIII in the normal range (≥66% of normal); 3) FVIII half-life ≥6 hours Wilate infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to \<5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU.

    Time frame: From ITI start until termination of study, a maximum of 2 years

Secondary outcomes

  1. Time Necessary to Achieve Complete or Partial ITI Success

    Time to achieve complete or partial ITI success will be determined using predefined success criteria. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre \<0.6 BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental IVR of FVIII in the normal range (≥66% of normal) ; 3) FVIII half-life ≥6 hours. Wilate infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to \<5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU. 0 participants analysed for this outcome due to termination of study.

    Time frame: A maximum period of 5 years from ITI start

  2. In Case of Complete or Partial ITI Success, Duration of Immune Tolerance

    Time from start of ITI success to end of study period

    Time frame: A maximum period of 5 years from ITI start

  3. Bleeding Frequency While on Wilate or Nuwiq ITI Treatment

    Bleeding episodes occurring during the study period will be documented by the patient or their parents in a patient study diary.

    Time frame: A maximum period of 5 years from ITI start

  4. Association of Inhibitor Titres With the Probability of ITI Success

    Inhibitor titre will be assessed at the start of and throughout ITI treatment, including peak inhibitor titres, with the probability of ITI success. ITI success will be determined using predefined success criteria. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre \<0.6 BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental IVR of FVIII in the normal range (≥66% of normal) ; 3) FVIII half-life ≥6 hours. Wilate or Nuwiq infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to \<5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU.

    Time frame: A maximum period of 5 years from ITI start

  5. Use of Bypassing Agents Before and During ITI Treatment With Wilate or Nuwiq

    Use of bypassing agents is at the discretion of the Investigator, either to treat bleeding or to provide prophylactic therapy. As long as the patient's inhibitor level is ≥0.6 Bethesda units (BU), treatment of BEs may, in addition to FVIII treatment, require the administration of activated prothrombin complex concentrates (aPCC) or recombinant FVIIa.

    Time frame: 12 months before the start of ITI with Wilate or Nuwiq to a maximum of 5 years from starting ITI with Wilate or Nuwiq

  6. Use of Emicizumab (Hemlibra) During ITI Treatment With Wilate or Nuwiq

    The dosing and frequency of emicizumab (Hemlibra) used is at the discretion of the Investigator. As a general guidance, the recommended dose is 3mg/kg once weekly for the first 4 weeks, followed by 1.5mg/kg once weekly, administered as a subcutaneous injection, as per the product monograph.

    Time frame: A maximum period of 5 years from ITI start

  7. Relapse Rate Following Complete or Partial Successful ITI Using Wilate or Nuwiq

    Reoccurrence of \>0.6 BU in at least 2 consecutive blood samples after having reached the prophylactic treatment phase; a further ITI initiation (re-start) with Wilate or Nuwiq is at the discretion of the Investigator.

    Time frame: A maximum period of 5 years from ITI start

  8. Time to Relapse Following Complete or Partial Successful ITI Using Wilate or Nuwiq

    Time to reoccurrence of \>0.6 BU in at least 2 consecutive blood samples after having reached the prophylactic treatment phase; a further ITI initiation (re-start) with Wilate or Nuwiq is at the discretion of the Investigator.

    Time frame: A maximum period of 5 years from ITI start

  9. Adherence With the ITI Regimen

    During ITI, any injections of Wilate or Nuwiq will be recorded in the patient study diary. The treating physician will review and verify the information provided by the patient.

    Time frame: A maximum period of 5 years from ITI start

07

Results

Posted Aug 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneWilate® Retrospective CohortWilate® Prospective Cohort
Started86
Completed66
Not completed20
Withdrew: Switched to alternative treatment10
Withdrew: Experienced a better response with recombinant activated factor vii (rfviia)10

Outcome measures

PrimaryNumber of Moderate and Severe Haemophilia A Patients With Inhibitors Achieving Complete or Partial Immune Tolerance Induction (ITI) Success

ITI success will be determined using predefined success criteria to analyze the proportion of patients achieving complete or partial ITI success. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre \<0.6BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental in vivo recovery (IVR) of FVIII in the normal range (≥66% of normal); 3) FVIII half-life ≥6 hours Wilate infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to \<5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU.

Time frame:
From ITI start until termination of study, a maximum of 2 years
Reported as:
Count of participants · Participants
Number of Moderate and Severe Haemophilia A Patients With Inhibitors Achieving Complete or Partial Immune Tolerance Induction (ITI) Success
ParticipantsWilate® Respective CohortWilate® Prospective Cohort
Complete success70
Partial success00
Partial failure00
Complete failure10
SecondaryTime Necessary to Achieve Complete or Partial ITI Success

Time to achieve complete or partial ITI success will be determined using predefined success criteria. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre \<0.6 BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental IVR of FVIII in the normal range (≥66% of normal) ; 3) FVIII half-life ≥6 hours. Wilate infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to \<5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU. 0 participants analysed for this outcome due to termination of study.

Time frame:
A maximum period of 5 years from ITI start

No measurements were reported for this outcome.

SecondaryIn Case of Complete or Partial ITI Success, Duration of Immune Tolerance

Time from start of ITI success to end of study period

Time frame:
A maximum period of 5 years from ITI start

No measurements were reported for this outcome.

SecondaryBleeding Frequency While on Wilate or Nuwiq ITI Treatment

Bleeding episodes occurring during the study period will be documented by the patient or their parents in a patient study diary.

Time frame:
A maximum period of 5 years from ITI start

No measurements were reported for this outcome.

SecondaryAssociation of Inhibitor Titres With the Probability of ITI Success

Inhibitor titre will be assessed at the start of and throughout ITI treatment, including peak inhibitor titres, with the probability of ITI success. ITI success will be determined using predefined success criteria. Complete success is defined by achieving all of the following variables: 1) Inhibitor titre \<0.6 BU (at least 2 separate blood samplings) assessed using the modified Bethesda assay; 2) Incremental IVR of FVIII in the normal range (≥66% of normal) ; 3) FVIII half-life ≥6 hours. Wilate or Nuwiq infusion. Partial success is defined as two of the three criteria being met, whilst partial response is defined as one of the three criteria being met. Partial failure is defined as none of the three criteria are met, but the inhibitor titre has decreased to \<5 BU; complete failure is defined as none of the three criteria are met, and the inhibitor titre is still ≥5 BU.

Time frame:
A maximum period of 5 years from ITI start

No measurements were reported for this outcome.

SecondaryUse of Bypassing Agents Before and During ITI Treatment With Wilate or Nuwiq

Use of bypassing agents is at the discretion of the Investigator, either to treat bleeding or to provide prophylactic therapy. As long as the patient's inhibitor level is ≥0.6 Bethesda units (BU), treatment of BEs may, in addition to FVIII treatment, require the administration of activated prothrombin complex concentrates (aPCC) or recombinant FVIIa.

Time frame:
12 months before the start of ITI with Wilate or Nuwiq to a maximum of 5 years from starting ITI with Wilate or Nuwiq

No measurements were reported for this outcome.

SecondaryUse of Emicizumab (Hemlibra) During ITI Treatment With Wilate or Nuwiq

The dosing and frequency of emicizumab (Hemlibra) used is at the discretion of the Investigator. As a general guidance, the recommended dose is 3mg/kg once weekly for the first 4 weeks, followed by 1.5mg/kg once weekly, administered as a subcutaneous injection, as per the product monograph.

Time frame:
A maximum period of 5 years from ITI start

No measurements were reported for this outcome.

SecondaryRelapse Rate Following Complete or Partial Successful ITI Using Wilate or Nuwiq

Reoccurrence of \>0.6 BU in at least 2 consecutive blood samples after having reached the prophylactic treatment phase; a further ITI initiation (re-start) with Wilate or Nuwiq is at the discretion of the Investigator.

Time frame:
A maximum period of 5 years from ITI start

No measurements were reported for this outcome.

SecondaryTime to Relapse Following Complete or Partial Successful ITI Using Wilate or Nuwiq

Time to reoccurrence of \>0.6 BU in at least 2 consecutive blood samples after having reached the prophylactic treatment phase; a further ITI initiation (re-start) with Wilate or Nuwiq is at the discretion of the Investigator.

Time frame:
A maximum period of 5 years from ITI start

No measurements were reported for this outcome.

SecondaryAdherence With the ITI Regimen

During ITI, any injections of Wilate or Nuwiq will be recorded in the patient study diary. The treating physician will review and verify the information provided by the patient.

Time frame:
A maximum period of 5 years from ITI start

No measurements were reported for this outcome.

Adverse events

Collected over Adverse drug reactions were monitored throughout the study from first treatment through to study termination, a maximum of 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Wilate® Retrospective Cohort0/8 (0%)1/8 (12.5%)0/8 (0%)
Wilate® Prospective Cohort0/6 (0%)1/6 (16.7%)1/6 (16.7%)
Most frequent serious events
Most frequent serious events
EventWilate® Retrospective CohortWilate® Prospective Cohort
Respiratory distressRespiratory, thoracic and mediastinal disorders0/81/6
Device-related infectionInfections and infestations1/80/6
GastroenteritisGastrointestinal disorders1/80/6
Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders1/80/6
Most frequent other events
Most frequent other events
EventWilate® Retrospective CohortWilate® Prospective Cohort
PyrexiaInfections and infestations0/81/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Wilate® Retrospective CohortWilate® Prospective CohortTotal
Mean10.6 ± 5.214.8 ± 7.312.4 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)Wilate® Retrospective CohortWilate® Prospective CohortTotal
Female000
Male8614
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Wilate® Retrospective CohortWilate® Prospective CohortTotal
Asian101
White549
Other123
Missing101
Blood type
Blood type(Participants)Wilate® Retrospective CohortWilate® Prospective CohortTotal
O325
A224
B101
AB123
Missing101
Severity of hemophilia A
Severity of hemophilia A(Participants)Wilate® Retrospective CohortWilate® Prospective CohortTotal
Mild527
Moderate112
Severe134
Missing101
FVIII mutation
FVIII mutation(Participants)Wilate® Retrospective CohortWilate® Prospective CohortTotal
Intron 22 Inversion336
Intron 1 Inversion101
Missense mutations011
Unknown325
Missing101
Previous inhibitor treatment
Previous inhibitor treatment(Participants)Wilate® Retrospective CohortWilate® Prospective CohortTotal
Yes6410
No224
08

Study locations

3 sites
  • Stollery children's hospital, University of Alberta
    Edmonton, Alberta, Canada
  • Children's Hospital of Eastern Ontario
    Ottawa, Ontario, Canada
  • Hamilton Health Science center
    Toronto, Ontario, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Nov 2020, 28 months.

Results were first posted in Aug 2024, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2017
First posted
Nov 17, 2017
StartActual
Jun 28, 2018
Primary completionActual
Nov 20, 2020
CompletionActual
Nov 20, 2020
Results first posted
Aug 9, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03344003
Lead sponsor
Octapharma
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Jun 28, 2018
Primary completion
Nov 20, 2020
Completion
Nov 20, 2020
Results posted
Aug 9, 2024
Last update
Aug 9, 2024

Study contacts

Sri Adapa
study director · Octapharma

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion